COMMUNIQUÉS West-GlobeNewswire

Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
12/03/2026
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
12/03/2026
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical [...]
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated [...]
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
12/03/2026
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial [...]
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
12/03/2026
- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential [...]
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
12/03/2026
Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report [...]
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana [...]
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
12/03/2026
CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
12/03/2026
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and [...]
Marine Biologics Unveils SeaTex™ For Clean Label Nutritional Design And Performance
12/03/2026
Novel single-ingredient seaweed powder designed for high-performance stabilization dramatically simplifies product formulations with zero additives or synthetic ingredients BERKELEY, Calif., March 12, 2026 (GLOBE [...]
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
12/03/2026
Application appuyée par des données de la Phase 3 renforçant les schémas thérapeutiques à base de teclistamab comme traitement standard potentiel après au moins une thérapie antérieure 1 La monothérapie par teclistamab [...]
Verano Announces $195 Million Senior Secured Term Loan Refinancing Agreement to Fund Company’s Strategic Growth Initiatives
12/03/2026
New credit facility highlights Company’s ability to access lower-cost regional bank capital and secure among the most favorable terms in the industry, including an initial 9.5% annual interest rate and prepayment [...]
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
12/03/2026
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or [...]
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
12/03/2026
Companies deepen partnership to advance automated, integrated microbiology quality control LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative [...]
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
12/03/2026
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March [...]
DigitalOptometrics® Announces Next Evolution in Tele-Ophthalmic Care at Vision Expo East
12/03/2026
Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- New partnership with Eyoto reinforces DigitalOptometrics’ leadership in delivering consistent, high-quality remote eye exams inside the clinic. Vision Expo East — [...]
Koelis Announces Innovative Products at EAU 2026 enhancing MRI Fusion Biopsy Workflows and promoting Focal Therapy in Prostate Cancer
12/03/2026
GRENOBLE, France, March 12, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced today [...]
Aclarion CEO Brent Ness to Attend LSI USA 2026
12/03/2026
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/03/2026
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted [...]

Pages